Premium
Riluzole results in improved hyperarousal symptoms in veterans with PTSD
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30678
Subject(s) - riluzole , placebo , antidepressant , medicine , posttraumatic stress , glutamatergic , fight or flight response , placebo response , psychiatry , clinical psychology , glutamate receptor , amyotrophic lateral sclerosis , anxiety , disease , receptor , pathology , biochemistry , gene , chemistry , alternative medicine
The glutamatergic modulator riluzole improved hyperarousal symptoms associated with post‐traumatic stress disorder (PTSD) in a group of military combat veterans, a placebo‐controlled trial has found. Although there were no significant overall differences between riluzole and placebo as augmentation of an antidepressant, the results suggest that riluzole augmentation could target specific PTSD symptoms in certain subgroups of patients with the disorder.